CareTrust REIT, Inc
CTRE
$35.79
-0.08%
CareTrust REIT, Inc. is a self-administered, publicly traded real estate investment trust that owns, acquires, finances, and develops skilled nursing, seniors housing, and other healthcare-related properties, generating revenue primarily through triple-net leases in which tenants bear property-level costs. The company occupies a distinct niche as a pure-play healthcare REIT with a highly concentrated portfolio and a small internal team of just 43 employees, positioning it as an agile, acquisition-driven consolidator rather than a diversified real estate platform. The current investor narrative centers on an aggressive external growth strategy: revenue nearly doubled year-over-year in the most recent quarter, driven by a wave of acquisitions funded through large equity raises, which has expanded the asset base but also increased share count and pressured per-share metrics. At the same time, the stock has materially lagged the broader market over the past year, and debate now hinges on whether the acquisition pipeline can translate into durable per-share earnings and dividend growth, or whether dilution and tenant credit risk in the skilled nursing space will continue to weigh on relative performance.…
CTRE
CareTrust REIT, Inc
$35.79
Investment Opinion: Should I buy CTRE Today?
Based on the synthesis, CTRE warrants a Hold rating. The core thesis is that the company's aggressive acquisition-driven growth is offset by dilution and per-share earnings pressure, but the strong analyst consensus (strong buy, average target $45.15) and discounted valuation relative to history suggest the risk/reward is balanced. The 24.4% upside to the average target is compelling, but the recent underperformance and negative momentum warrant caution. Supporting evidence includes: 1) Revenue growth of 99.3% year-over-year in Q1 2026, though per-share growth is much lower due to a 19.1% increase in shares outstanding; 2) Profitability remains robust with EBITDA margin of 85.8% and net margin of 56.2%, but net margin has compressed from 91.8% a year ago due to higher interest expense; 3) The dividend yield of 3.52% is attractive, but the payout ratio of 80.9% limits growth; 4) Valuation is below historical averages (PE of 23.0x vs. 25.5x in Q1 2026 and 36.7x in Q3 2024), suggesting much bad news is priced in. Risks that could invalidate the thesis include: a breakdown below the 52-week low of $32.79, a significant tenant default, or a slowdown in acquisition accretion. The rating would upgrade to Buy if per-share earnings growth accelerates (e.g., EPS growth above 12.5% as implied by forward PE) or if the stock reclaims the $40-$42 resistance area. It would downgrade to Sell if revenue growth decelerates below 20% or if the payout ratio exceeds 90%. Relative to its history and peers, CTRE appears fairly valued to slightly undervalued, but the market is demanding evidence of per-share growth before re-rating.
Sign up to view all
CTRE 12-Month Price Forecast
CTRE presents a balanced risk/reward profile, with strong revenue growth and a discounted valuation offset by dilution and margin pressure. The analyst consensus is overwhelmingly bullish, but the market has been skeptical, as evidenced by significant underperformance. The key to unlocking value is demonstrating per-share earnings growth from acquisitions, which would likely drive multiple expansion. We would upgrade to bullish if per-share EPS growth accelerates above 12.5% or if the stock reclaims $40-$42 resistance. We would downgrade to bearish if revenue growth decelerates below 20% or if tenant credit issues emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CareTrust REIT, Inc's 12-month outlook, with a consensus price target around $44.77 and implied upside of +25.1% versus the current price.
Average Target
$44.77
0 analysts
Implied Upside
+25.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$42 - $49
Analyst target range
Coverage of CareTrust is solid, with 13 analysts contributing to a consensus recommendation of "strong buy" and a recommendation mean of 1.31, where 1.0 represents a strong buy and 5.0 a sell. The average price target of $45.15 implies roughly 24.4% upside from the current price of $36.30, a notably bullish signal given the stock's recent underperformance. The consensus leans decisively bullish, and the institutional ratings history shows no downgrades over the past year, with BMO Capital upgrading the shares to Outperform from Market Perform in January 2026 and firms including Wells Fargo, RBC Capital, UBS, and Jefferies maintaining positive ratings through mid-2026. The target range spans $43.00 to $49.00, a spread of about 14% around the average, which signals reasonably strong conviction rather than wide disagreement. The high target of $49.00 implies roughly 35% upside and likely assumes successful deployment of the acquisition pipeline, multiple expansion back toward historical averages, and continued dividend growth; the low target of $43.00 still implies about 18% upside and appears to price in a more conservative scenario of steady but unspectacular per-share growth with stable margins. Notably, even the lowest analyst target sits above the current price, suggesting the sell-side views the recent 13% three-month decline as an overreaction rather than a fundamental deterioration, though the persistent gap between consensus optimism and market pricing is itself a risk factor worth monitoring.
Drowning in data?
Find the real signal!
Bulls vs Bears: CTRE Investment Factors
The bear case currently has stronger evidence due to CTRE's severe relative underperformance (-16.41% vs. SPY over three months), negative momentum, and dilution concerns that have pressured per-share metrics. However, the bull case is supported by a strong analyst consensus (13 analysts, strong buy rating) and a 24.4% upside to the average target, suggesting the sell-side sees the decline as overdone. The most important tension is whether the acquisition pipeline can translate into accelerating per-share earnings and dividend growth, or whether dilution and tenant credit risks will continue to weigh on performance. If per-share growth accelerates, the stock could re-rate toward historical multiples; if not, it may remain range-bound or drift lower. The resolution of this tension will likely determine CTRE's trajectory over the next 12 months.
Bullish
- Analyst consensus strong buy with 24% upside: 13 analysts rate CTRE a strong buy (recommendation mean 1.31), with an average price target of $45.15, implying 24.4% upside from $36.30. Even the lowest target of $43.00 suggests 18.5% upside, indicating the sell-side views the recent decline as an overreaction.
- Revenue nearly doubled YoY in Q1 2026: Q1 2026 revenue surged 99.3% year-over-year to $142.78 million, driven by an aggressive acquisition program. This growth trajectory, if sustained, could drive significant per-share earnings expansion as newly acquired properties stabilize.
- Conservative balance sheet with low leverage: Debt-to-equity is just 0.222 and the current ratio is 1.54, providing ample financial flexibility. This low leverage allows CTRE to fund acquisitions with debt if equity markets become less favorable, reducing dilution risk.
- Attractive dividend yield with room to grow: The stock offers a 3.52% dividend yield, well above the S&P 500 average, and the payout ratio of 80.9% is sustainable given trailing free cash flow of $397.1 million. As earnings grow, the dividend could rise further, enhancing total return.
Bearish
- Severe relative underperformance and negative momentum: CTRE has underperformed SPY by 16.41 percentage points over three months and 22.62 points over six months, with the stock down 13.07% in three months. This persistent weakness suggests institutional selling and loss of confidence.
- Dilution from aggressive equity issuance: Shares outstanding rose from 187.2 million in Q1 2025 to 223.0 million in Q1 2026, a 19.1% increase, far outpacing per-share growth. This dilution pressures EPS and dividend growth, undermining the acquisition strategy's per-share accretion.
- Rising interest expense compressing margins: Interest expense more than doubled to $11.24 million in Q1 2026 from $6.67 million a year earlier, contributing to a net margin decline from 91.8% to 56.2%. Further rate increases could exacerbate this pressure.
- High payout ratio limits financial flexibility: The dividend payout ratio of 80.9% leaves little cushion, with Q1 2026 dividends of $74.8 million against operating cash flow of $90.4 million. Any earnings shortfall could jeopardize the dividend or force further external financing.
CTRE Technical Analysis
CTRE is in a broad, range-bound consolidation with a deteriorating intermediate-term trend. The stock is up just 3.51% over the past year, dramatically underperforming SPY's 15.01% gain, and at a current price of $36.30 it sits at roughly 32.4% of its 52-week range of $32.79 to $43.62, placing it in the lower third of that band. That positioning signals neither a momentum breakout nor a deep-value washout, but rather a stock that has lost its bid while holding above major support, leaving it vulnerable to further drift if buyers do not step in near the lower boundary. Recent momentum is clearly negative and diverging from the already-modest one-year trend. The stock is down 8.26% over the past month and 13.07% over three months, with the 3-month decline far exceeding the 1-year gain, indicating that the longer-term uptrend has rolled over into a corrective phase. Relative strength confirms the weakness: CTRE has underperformed SPY by 8.85 percentage points over one month and 16.41 points over three months, one of the sharper divergences in the data set, suggesting persistent institutional selling rather than a temporary pullback. Key technical levels are well defined. Support rests at the 52-week low of $32.79, roughly 9.7% below the current price, while resistance sits at the 52-week high of $43.62, about 20.2% above. A breakdown below $32.79 would signal a full trend reversal and likely invite momentum-driven selling, whereas a reclaim of the $40-$42 area would be needed to repair the chart. With a beta of 0.787, CTRE is roughly 21% less volatile than the broader market, which softens the impact of drawdowns but also means it will likely lag in sharp risk-on rallies; the maximum drawdown of -17.26% reflects this relatively defensive profile.
Beta
0.77
0.77x market volatility
Max Drawdown
-17.5%
Largest decline past year
52-Week Range
$33-$44
Price range past year
Annual Return
+5.3%
Cumulative gain past year
| Period | CTRE Return | S&P 500 |
|---|---|---|
| 1m | -9.0% | +1.0% |
| 3m | -11.0% | +2.5% |
| 6m | -9.8% | +13.9% |
| 1y | +5.3% | +15.0% |
| ytd | -1.4% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTRE Fundamental Analysis
CareTrust's revenue trajectory is one of rapid expansion, though the quality of that growth warrants scrutiny. Q1 2026 revenue reached $142.78 million, up 99.3% year-over-year from $71.65 million in Q1 2025, continuing a multi-quarter acceleration from $86.03 million in Q2 2025 and $104.27 million in Q3 2025. The company reports a single reportable segment, so growth is entirely driven by the healthcare real estate portfolio, funded by a substantial acquisition program; however, the pace of share issuance, with shares outstanding rising from 187.2 million in Q1 2025 to 223.0 million in Q1 2026, means per-share growth is far more modest than headline revenue growth, and investors should monitor whether acquisitions are accretive on a per-share basis. Profitability is robust at the operating level, though reported net income is flattered by non-cash items. Q1 2026 net income was $80.21 million on revenue of $142.78 million, a net margin of 56.2%, while gross margin was 56.9% and operating margin 65.1%. The net margin has compressed from 82.4% in Q4 2025 and 91.8% in Q1 2025, largely reflecting higher interest expense ($11.24 million in Q1 2026 versus $6.67 million a year earlier) and a rising depreciation base as the portfolio expands; EBITDA of $122.45 million remains strong at 85.8% of revenue, consistent with the triple-net lease model's high-margin economics. The balance sheet is conservatively positioned but cash flow coverage of the dividend is tight. Debt-to-equity stands at just 0.222, and the current ratio of 1.54 indicates adequate liquidity, while trailing free cash flow of $397.1 million comfortably exceeds the annualized dividend outlay implied by the 80.9% payout ratio. However, ROE of 7.94% and ROA of 4.44% are modest for a REIT, and the Q1 2026 dividend payment of $74.8 million against operating cash flow of $90.4 million leaves limited cushion; the company remains dependent on external equity and debt financing to fund its acquisition pipeline, as evidenced by $127.9 million of common stock issued in Q1 2026 alone.
Quarterly Revenue
$142783000.0B
2026-03
Revenue YoY Growth
+99.3%
YoY Comparison
Gross Margin
56.9%
Latest Quarter
Free Cash Flow
$397136000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTRE Overvalued?
Because CareTrust is profitable, with trailing net income positive and EPS of $0.044 on a trailing basis, the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 23.0x versus a forward PE of 20.5x, and the gap implies the market expects earnings growth of roughly 12.5% over the next year, consistent with analyst EPS estimates of $1.90 for the forward period. On a price-to-book basis, the shares change hands at 1.82x, a modest premium to book that reflects the REIT's tangible asset backing. Relative to sector norms, CTRE's valuation is mixed. Its 23.0x trailing PE is above the typical healthcare REIT range in the mid-to-high teens, and its price-to-sales ratio of 15.45x and EV/EBITDA of 17.44x are elevated for a triple-net landlord, reflecting the market's willingness to pay up for the company's acquisition-driven growth story. The 3.52% dividend yield is competitive for the sector and provides a meaningful component of total return, but the 80.9% payout ratio limits the room for aggressive dividend increases without further earnings growth. Against its own history, the stock is not expensive: the PE of 23.0x is below the 25.5x recorded in Q1 2026 and well below the 36.7x seen in Q3 2024, while the price-to-book of 1.82x is near the lower end of its multi-year range of roughly 1.69x to 2.42x. This suggests the market has already de-rated the shares in response to dilution and slowing per-share growth, meaning much of the bad news may be priced in, but a re-rating will require evidence that acquisitions are translating into accelerating per-share earnings.
PE
23.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are centered on CTRE's aggressive acquisition strategy and its impact on per-share metrics. Shares outstanding increased 19.1% year-over-year to 223.0 million, significantly diluting per-share earnings and dividends, while interest expense more than doubled to $11.24 million in Q1 2026. The dividend payout ratio of 80.9% leaves minimal cushion, with Q1 2026 dividends of $74.8 million against operating cash flow of $90.4 million, forcing reliance on external financing. Additionally, the portfolio is concentrated in skilled nursing facilities, exposing CTRE to tenant credit risk and regulatory changes in healthcare reimbursement. Market and competitive risks include CTRE's elevated valuation relative to peers, with a trailing PE of 23.0x and price-to-sales of 15.45x, which could compress if growth slows. The stock's beta of 0.787 indicates lower volatility than the market, but it has still underperformed SPY by 16.41 percentage points over three months, reflecting sector rotation away from healthcare REITs and concerns about interest rates. Competitive pressures from other REITs and private buyers for healthcare assets could drive up acquisition prices, reducing future returns. In a worst-case scenario, a breakdown below the 52-week low of $32.79 (9.7% below current price) could trigger momentum selling, while a significant tenant default or regulatory change could push the stock toward the analyst low target of $43.00, though that is above current levels; a more severe scenario might see a decline to the 52-week low, representing a 9.7% loss from current levels, or worse if fundamentals deteriorate further.
FAQ
The key risks include: 1) Dilution risk, as shares outstanding increased 19.1% year-over-year, pressuring per-share metrics; 2) Tenant credit risk, given the concentration in skilled nursing facilities, which are vulnerable to regulatory and reimbursement changes; 3) Interest rate risk, with interest expense more than doubling to $11.24 million in Q1 2026, and further hikes could compress margins; 4) Dividend risk, as the payout ratio of 80.9% leaves little cushion, and a earnings shortfall could force a dividend cut or further external financing. These risks are ranked from high to moderate, with dilution and tenant credit being the most immediate concerns.
Our 12-month forecast for CTRE includes three scenarios: bull case (30% probability) with a target range of $45-$49, base case (50% probability) with a target range of $40-$45, and bear case (20% probability) with a target range of $32.79-$36. The base case is most likely, assuming revenue growth decelerates to 20-30% and per-share EPS grows in line with analyst estimates of $1.90. The key assumption is that acquisitions are accretive and interest rates remain stable. The analyst average target of $45.15 aligns with our base case upper bound, implying 24.4% upside.
CTRE appears fairly valued to slightly undervalued relative to its own history, with a trailing PE of 23.0x below the 25.5x seen in Q1 2026 and 36.7x in Q3 2024. However, it trades at a premium to the broader healthcare REIT sector, with a price-to-sales of 15.45x and EV/EBITDA of 17.44x. The price-to-book of 1.82x is near the low end of its multi-year range, suggesting the market has already de-rated the stock. The forward PE of 20.5x implies earnings growth of 12.5%, which seems achievable if acquisitions are accretive. Overall, the valuation is not stretched, but a re-rating depends on per-share growth acceleration.
CTRE may be a good buy for income-oriented investors with a long-term horizon, given its 3.52% dividend yield and 24.4% upside to the average analyst target of $45.15. However, the stock has significantly underperformed the market, down 13.07% over three months, and faces dilution and margin pressures. The strong buy consensus from 13 analysts suggests the sell-side sees value, but the market is demanding evidence of per-share growth. A good entry point might be near the 52-week low of $32.79, which offers a margin of safety. Investors should be prepared for volatility and monitor quarterly results for signs of accretion.
CTRE is more suitable for long-term investment, given its dividend yield of 3.52% and the time needed for acquisitions to translate into per-share growth. The stock's beta of 0.787 indicates lower volatility than the market, but it has still experienced a max drawdown of -17.26% and significant underperformance. Short-term trading is risky due to negative momentum and the potential for further downside. A minimum holding period of 2-3 years is recommended to allow the acquisition pipeline to mature and for per-share metrics to improve. Income investors may appreciate the dividend, but they should monitor the payout ratio and tenant health.
